Vaccitech Q1 net loss $18.2M vs $2.6M income; cash $191.3M; positive HBV, HPV data

Barinthus Biotherapeutics plc.

2023-Q1 EPS reported -$0.48 revenue$468,000

Net loss per share $0.48 vs prior year income $0.07; revenue fell to $0.5M from $15.0M due to lower Vaxzevria royalties.
Cash $191.3M at March 31, 2023, down from $194.4M; cash runway into Q1 2025.
HBV002 trial met endpoints; meaningful HBsAg reductions; final data to be presented at EASL June 21-24.
APOLLO HPV trial showed favorable tolerability and T-cell responses; final 12-month data expected Q2 2024.
Appointed Nadège Pelletier as CSO; COO Chris Ellis to retire Oct 31, 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Barinthus Biotherapeutics plc. reported financial results for the first quarter of 2023.

Period: the first quarter of 2023
Result: reported results

Exact text from the filing

today announced its financial results for the first quarter of 2023

View on SEC.gov

Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001104659-23-059424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.